Zolpidem

Eisai To Present Latest Data of Lemborexant at 35th Annual Sleep Meeting (SLEEP2021)

Wednesday, June 9, 2021 - 3:31am

TOKYO, June 9, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that a total of 5 poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 35th annual meeting of the Associated Professional Sleep Societies (SLEEP 2021), to be held virtually from June 10 to 13, 2021.

Key Points: 
  • TOKYO, June 9, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that a total of 5 poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 35th annual meeting of the Associated Professional Sleep Societies (SLEEP 2021), to be held virtually from June 10 to 13, 2021.
  • Major poster presentations include the results of a study evaluating next-dose transition from zolpidem to lemborexant for insomnia treatment (Poster Numbers: #335 and #337).
  • Eisai considers neurology a therapeutic area of focus.
  • Eisai strives to create innovative products in therapeutic areas with high unmet medical needs as soon as possible, and will further contribute to addressing the diverse needs of, as well as increasing the benefits provided to, those living with neurological diseases and their families.

Eisai to Present Latest Insomnia Research, Including Data on New Treatment DAYVIGO™ (lemborexant) CIV, at the SLEEP 2020 Virtual Conference

Monday, August 24, 2020 - 1:10pm

Additional research to be presented will explore sleep onset and sleep maintenance responder profiles over 12 months of treatment with DAYVIGO, efficacy and safety of DAYVIGO in females of perimenopausal age with insomnia disorder, and impact of DAYVIGO treatment on fatigue severity.

Key Points: 
  • Additional research to be presented will explore sleep onset and sleep maintenance responder profiles over 12 months of treatment with DAYVIGO, efficacy and safety of DAYVIGO in females of perimenopausal age with insomnia disorder, and impact of DAYVIGO treatment on fatigue severity.
  • In addition, interim results from a multi-center pilot study evaluating the next-dose transition from zolpidem to DAYVIGO for the treatment of insomnia will be presented.
  • DAYVIGO (lemborexant) is an orexin receptor antagonist indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
  • CNS depressant effects may persist in some patients up to several days after discontinuing DAYVIGO.

2020 Zolpidem Market Study: Worldwide Trends & Developments, Major Players, Patents, and More

Tuesday, March 31, 2020 - 11:30am

DUBLIN, March 31, 2020 /PRNewswire/ -- The "Zolpidem (CAS 82626-48-0) Market Research Report 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 31, 2020 /PRNewswire/ -- The "Zolpidem (CAS 82626-48-0) Market Research Report 2020" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Zolpidem.
  • The report helps to build up a clear view of the market trends and development, identify major players in the industry, and estimate main downstream sectors.
  • The Zolpidem global market report key points:

Global Zolpidem Market Research Report, 2020 - ResearchAndMarkets.com

Monday, March 30, 2020 - 11:33am

The "Zolpidem (CAS 82626-48-0) Market Research Report 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Zolpidem (CAS 82626-48-0) Market Research Report 2020" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Zolpidem.
  • The report helps to build up a clear view of the market trends and development, identify major players in the industry, and estimate main downstream sectors.
  • The Zolpidem global market report key points:

FDA requires stronger warnings about rare but serious incidents related to certain prescription insomnia medicines

Tuesday, April 30, 2019 - 6:19pm

The boxed warning follows several reports of rare, but serious injuries and deaths resulting from various complex sleep behaviors after taking these medicines.

Key Points: 
  • The boxed warning follows several reports of rare, but serious injuries and deaths resulting from various complex sleep behaviors after taking these medicines.
  • The new warnings will be required for eszopiclone (Lunesta), zaleplon (Sonata) and zolpidem (Ambien, Ambien CR, Edluar, Intermezzo, and Zolpimist).
  • "We recognize that millions of Americans suffer from insomnia and rely on these drugs to help them sleep better at night.
  • While these incidents are rare, they are serious and it's important that patients and health care professionals are aware of the risk.

Stilnox - API Insight, 2019-2021: Historical & Forecasted Sales Analysis - ResearchAndMarkets.com

Friday, April 5, 2019 - 4:23pm

The "Stilnox - API Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Stilnox - API Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Stilnox - API Insight, 2019 provides product and API manufacturers' details across the globe along with the location.
  • The report gives the clear idea on the country wise DMF filed by worldwide companies related to Stilnox.
  • The report also highlights the patent details of Stilnox.

Stilnox - Drug Insight, 2019 - ResearchAndMarkets.com

Friday, February 1, 2019 - 4:16pm

The "Stilnox - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Stilnox - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.
  • Stilnox Drug Insight, 2019 highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location.
  • The report also covers the patents information and market exclusivity data, route of synthesis, market competition, and API manufacturers by country.
  • In addition to this, the report also provides the SWOT analysis for Stilnox and emerging therapies in this space.

New Drug Application for Insomnia Disorder Treatment Lemborexant Submitted in the United States

Tuesday, January 15, 2019 - 1:01pm

In addition to the treatment of insomnia disorder, a Phase 2 clinical study of lemborexant in patients with irregular sleep-wake rhythm disorder and mild to moderate Alzheimer's dementia is underway.

Key Points: 
  • In addition to the treatment of insomnia disorder, a Phase 2 clinical study of lemborexant in patients with irregular sleep-wake rhythm disorder and mild to moderate Alzheimer's dementia is underway.
  • In this study, patients were randomized to receive placebo or one of three treatment regimens (lemborexant 5 mg, lemborexant 10 mg, zolpidem ER 6.25 mg).
  • During the active-only treatment period, patients who received placebo during the first period were re-randomized to receive lemborexant 5 mg or 10 mg.
  • Patients who received active treatment during the first period continued on the treatment to which they were originally randomized.

2018 Market Spotlight for Insomnia - Belsomra is Forecasted to Overtake Ambien to Have the Highest Revenues, Peaking in 2021

Wednesday, May 23, 2018 - 7:30pm

It is estimated that Asia had the largest number of prevalent cases in 2016, despite having the lowest prevalence proportion (665 million cases; 15%).

Key Points: 
  • It is estimated that Asia had the largest number of prevalent cases in 2016, despite having the lowest prevalence proportion (665 million cases; 15%).
  • During 2018-22, Belsomra is forecasted to overtake Ambien to have the highest revenues, peaking in 2021.
  • Takeda has the highest number of completed clinical trials for insomnia, with 63 trials.
  • Takeda also leads industry sponsors with the highest number of clinical trials overall for insomnia, followed by Merck & Co, Pfizer, and Sanofi